Bayesian Capital Management’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.2K Buy
+14,500
New +$35.4K 0.02% 222
2025
Q2
Sell
-22,900
Closed -$98.9K 784
2025
Q1
$98.9K Buy
+22,900
New +$92.5K 0.02% 542
2024
Q3
Sell
-10,584
Closed -$29.6K 950
2024
Q2
$29.6K Buy
10,584
+300
+3% +$805 ﹤0.01% 675
2024
Q1
$29.2K Sell
10,284
-5,800
-36% -$19.7K ﹤0.01% 743
2023
Q4
$65.8K Buy
+16,084
New +$45K 0.01% 671
2022
Q2
Sell
-39,900
Closed -$304K 994
2022
Q1
$304K Buy
+39,900
New +$309K 0.05% 515

Other funds holding ORGO

Bayesian Capital Management's ORGO Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Organogenesis Holdings (ORGO) in Q2 2026: 14,500 shares worth $35.2K. The stake represents 0.02% of the portfolio and ranks #222 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in ORGO as recently as Q1 2025.

Bayesian Capital Management first reported a position in ORGO in Q1 2022 and has held it in 6 quarters since. The position peaked at $304K in Q1 2022. 136 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Bayesian Capital Management held 14,500 shares of Organogenesis Holdings worth $35.2K as of Q2 2026.
  • Organogenesis Holdings was a new Bayesian Capital Management position in Q2 2026.
  • Organogenesis Holdings made up 0.02% of Bayesian Capital Management's portfolio in Q2 2026, its #222 holding.
  • Bayesian Capital Management first reported a position in Organogenesis Holdings in Q1 2022 and has held it in 6 quarters since.
  • Bayesian Capital Management's Organogenesis Holdings position peaked at $304K in Q1 2022.
  • 136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.